"compound 25"

mutant KRASG12C allosteric covalent inhibitor

orally efficacious in XG model

from optimization of literature starting point

J. Med. Chem. Feb. 5, 2020

AstraZeneca, Cambridge, UK

KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks